Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have a poor prognosis. In this setting, recruitment into clinical trials is warranted, and studies driven by selection according to individual tumor molecular characteristics are expected to provide added...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartore-Bianchi, Andrea, Amatu, Alessio, Bonazzina, Erica, Stabile, Stefano, Giannetta, Laura, Cerea, Giulio, Schiavetto, Ilaria, Bencardino, Katia, Funaioli, Chiara, Ricotta, Riccardo, Cipani, Tiziana, Schirru, Michele, Gambi, Valentina, Palmeri, Laura, Carlo-Stella, Giulia, Rusconi, Francesca, Di Bella, Sara, Burrafato, Giovanni, Cassingena, Andrea, Valtorta, Emanuele, Lauricella, Calogero, Pazzi, Federica, Gambaro, Alessandra, Ghezzi, Silvia, Marrapese, Giovanna, Tarenzi, Emiliana, Veronese, Silvio, Truini, Mauro, Vanzulli, Angelo, Siena, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524857/
https://www.ncbi.nlm.nih.gov/pubmed/28669023
http://dx.doi.org/10.1007/s11523-017-0505-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524857/
https://www.ncbi.nlm.nih.gov/pubmed/28669023
http://dx.doi.org/10.1007/s11523-017-0505-6

Ejemplares similares